The Graves Diseases drugs in development market research report provides comprehensive information on the therapeutics under development for Graves Diseases, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Graves Diseases. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Graves Diseases and features dormant and discontinued products.
GlobalData tracks 13 drugs in development for Graves Diseases by 13 companies/universities/institutes. The top development phase for Graves Diseases is preclinical with eight drugs in that stage. The Graves Diseases pipeline has 13 drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Graves Diseases pipeline products market are: HanAll Biopharma, Tourmaline Bio and Crinetics Pharmaceuticals.
The key targets in the Graves Diseases pipeline products market include Thyrotropin Receptor, IgG Receptor FcRn Large Subunit p51, and Interleukin 6.
The key mechanisms of action in the Graves Diseases pipeline product include Thyrotropin Receptor Antagonist with four drugs in Preclinical. The Graves Diseases pipeline products include three routes of administration with the top ROA being Subcutaneous and four key molecule types in the Graves Diseases pipeline products market including Monoclonal Antibody, and Small Molecule.
Graves Diseases overview
Graves’ disease is an immune system disorder that results in the overproduction of thyroid hormones (hyperthyroidism). Symptoms include anxiety, weight loss, change in menstrual cycles, erectile dysfunction, bulging eyes, and irregular heartbeat. Risk factors include family history, age, autoimmune disorders, smoking, and pregnancy. Treatment includes anti-thyroid medications, beta blockers, and surgery.
For a complete picture of Graves Diseases’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
